GoodRx (NASDAQ:GDRX) PT Lowered to $6.50

GoodRx (NASDAQ:GDRXGet Rating) had its price target dropped by investment analysts at Cowen to $6.50 in a research report issued to clients and investors on Wednesday, Stock Target Advisor reports. Cowen’s price objective suggests a potential upside of 31.05% from the stock’s previous close.

A number of other research analysts have also weighed in on GDRX. Barclays reduced their price objective on shares of GoodRx from $13.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, October 11th. JPMorgan Chase & Co. raised GoodRx from an “underweight” rating to a “neutral” rating and dropped their price objective for the stock from $10.00 to $8.00 in a report on Friday, November 4th. Royal Bank of Canada reduced their target price on GoodRx from $11.00 to $6.00 and set a “sector perform” rating for the company in a report on Wednesday, November 9th. Credit Suisse Group increased their price target on shares of GoodRx from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, August 9th. Finally, The Goldman Sachs Group reduced their price objective on shares of GoodRx from $10.00 to $8.00 and set a “neutral” rating for the company in a research note on Wednesday, November 9th. Fifteen equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $13.28.

GoodRx Price Performance

GDRX opened at $4.96 on Wednesday. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of -29.17, a PEG ratio of 10.55 and a beta of 0.98. The company has a quick ratio of 10.34, a current ratio of 10.34 and a debt-to-equity ratio of 0.83. The firm has a 50-day moving average price of $5.23 and a 200-day moving average price of $6.53. GoodRx has a twelve month low of $3.82 and a twelve month high of $42.87.

Institutional Investors Weigh In On GoodRx

Institutional investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. lifted its stake in GoodRx by 1,233.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 5,066 shares of the company’s stock worth $30,000 after purchasing an additional 4,686 shares during the last quarter. Ensign Peak Advisors Inc bought a new stake in shares of GoodRx in the 3rd quarter valued at about $42,000. Levin Capital Strategies L.P. purchased a new stake in GoodRx during the 3rd quarter valued at about $47,000. Quadrature Capital Ltd bought a new position in GoodRx during the 3rd quarter worth approximately $58,000. Finally, Victory Capital Management Inc. purchased a new position in GoodRx in the 2nd quarter worth approximately $59,000. Hedge funds and other institutional investors own 39.16% of the company’s stock.

GoodRx Company Profile

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Further Reading

Stock Target Advisor logo

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.